Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)